EUVIMEDEUVIMED entdecken
Open Access

Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer

Yang Yuan, Shaohua Zhang, Tao Wang, Biyun Wang, Shusen Wang, Jing Shi, Tao Sun, Yongmei Yin, Quchang Ouyang, Jianbin Li, Yi Wen, Lijun Zhang und 1 weitere

Translational Breast Cancer Research · 2023-04 · 4 · 10-10

DOI: 10.21037/tbcr-23-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Breast Cancer Research, 2023-04. Verfasst von Yang Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Fifth Medical Centre of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorabemaciclibhormone receptor-positive metastatic breast cancer (HR+ MBC)progressiontucidinostat

Autor:innen und Institutionen

  • Department of Oncology, The Fifth Medical Centre of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Oncology, The First Hospital of China Medical Hospital, Shenyang, China.
  • Department of Oncology, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China.
  • Department of Breast Cancer, Jiangsu Province Hospital & The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Zitieren

APA

Yuan, Y., Zhang, S., Wang, T., Wang, B., Wang, S., Shi, J., Sun, T., Yin, Y., Ouyang, Q., Li, J., Wen, Y., Zhang, L., & Jiang, Z. (2023). Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer. Translational Breast Cancer Research, 4, 10-10. https://doi.org/10.21037/tbcr-23-9

Vancouver

Yuan Y, Zhang S, Wang T, Wang B, Wang S, Shi J, et al. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer. Translational Breast Cancer Research. 2023;4:10-10. doi:10.21037/tbcr-23-9

BibTeX
@article{Yuan2023,
  author = {Yuan, Yang and Zhang, Shaohua and Wang, Tao and Wang, Biyun and Wang, Shusen and Shi, Jing and Sun, Tao and Yin, Yongmei and Ouyang, Quchang and Li, Jianbin and Wen, Yi and Zhang, Lijun and Jiang, Zefei},
  title = {Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+HER2− metastatic breast cancer},
  journal = {Translational Breast Cancer Research},
  year = {2023},
  volume = {4},
  pages = {10--10},
  doi = {10.21037/tbcr-23-9}
}
Kostenlos starten →